⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models USA - English APAC - Traditional Chinese APAC - English
prnewswire.com
LLY
Chainguard Launches Commercial Builds with Industry Leaders, Setting a New Standard for Verifiable, Zero-Vulnerability Software
prnewswire.com
ESTC
GLBZ
GRAF
TIGR
SNOW
FTNT
HPE
OPEN
CHKP
CAN
PANW
CRWD
ZS
DDOG
MDB
SMCI
AMD
NVDA
INTC
AMZN
GOOG
MSFT
IBM
ORCL
CRM
ADBE
PYPL
NFLX
CMCSA
DIS
VZ
T
KO
PEP
JNJ
PG
XOM
CVX
UNH
JPM
BAC
WFC
C
GS
MS
AMGN
GILD
BMY
PFE
MRK
ABBV
LLY
MDT
ISRG
COST
WMT
HD
MCD
SBUX
NKE
BA
CAT
GE
HON
RTX
LMT
GD
MMC
AXP
V
MA
MSCI
ADP
AMAT
ASML
QCOM
AVGO
TXN
ADSK
CDNS
SNPS
MRVL
GOOGL
Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™
globenewswire.com
LLY
Ulrich Wendt joins UK biotech Alchemab Therapeutics as Chief Business Officer to expand biopharma partnerships
businesswire.com
SNY
LLY
GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors
prnewswire.com
LLY
BIIB
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
prnewswire.com
LLY
BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
globenewswire.com
JNJ
LLY
NVO
TEVA
GSK
IFNNY
Liberty All-Star® Growth Fund, Inc. February 2026 Monthly Update
businesswire.com
NVDA
AAPL
GOOGL
MSFT
META
AMZN
CW
OLLI
AVGO
LGN
MPWR
ARTV
ASND
LLY
NVT
CAT
FTAI
LOW
PLTR
TKO
PINS
UNH
Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients
prnewswire.com
KR
LLY
Form Health Joins the Lilly Employer Connect Platform
businesswire.com
LLY